Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
A randomized trial demonstrates that a simplified bowel preparation using clear liquids and water offers comparable diagnostic yield and cleanliness to PEG-based regimens for Crohn’s disease capsule endoscopy, while significantly improving
Clinical trials reveal that Rifaximin provides faster symptom relief and significantly better adherence than the low FODMAP diet in IBS patients, while also potentially restoring lactase activity in those with small intestinal bacterial ove
A new serum cytokine-based risk score (CYTOscore) utilizing IL-8, CCL3, and CCL4 identifies ESCC patients likely to benefit from chemoradiotherapy combined with toripalimab, offering a non-invasive tool for personalized immunotherapy and pr
A multicenter RCT found that ethosuximide, a T-type calcium channel blocker, did not improve abdominal pain in IBS patients compared to placebo and was associated with significant tolerability issues, highlighting the need for more selectiv
This article explores the unique epidemiological landscape of anal canal cancer in Japan, highlighting the predominance of adenocarcinoma over squamous cell carcinoma and the rising role of chemoradiotherapy in clinical management.
The 5-year update of the CinClare trial demonstrates that adding irinotecan to neoadjuvant chemoradiotherapy, guided by UGT1A1 genotype, significantly improves long-term survival and disease-free outcomes in patients with locally advanced r
By 2050, global gastrointestinal cancer incidence is projected to surge by 85%, reaching 9.06 million cases annually. While gastric cancer rates are declining, colorectal and pancreatic cancers are rising sharply, particularly in low and me
The Phase 2 ACC trial demonstrates that adjuvant camrelizumab combined with capecitabine achieves a median recurrence-free survival of 24.29 months for patients with resected intrahepatic cholangiocarcinoma, offering a promising and managea
A Phase 2 trial demonstrates that tinengotinib, a multi-kinase inhibitor, shows significant clinical activity in patients with advanced cholangiocarcinoma who have progressed on prior FGFR inhibitors, particularly those with acquired resist
The 24-week results of the IMPACT trial show that pemvidutide significantly improves MASH resolution without worsening fibrosis. While fibrosis improvement did not reach significance at this early time point, the drug’s safety profile
The Phase 2b IMPACT trial demonstrates that pemvidutide, a GLP-1/glucagon dual agonist, significantly achieves MASH resolution at 24 weeks without dose titration, though fibrosis improvement did not reach significance at this early timepoin
Researchers have discovered that Zhenqi Fuzheng Granule enhances PD-1 antibody efficacy in colorectal cancer by modulating the gut microbiota-SCFA-GPR109A axis, effectively suppressing tumor glycolysis and reversing immune exhaustion within
A multi-institutional analysis reveals that HER2-positivity in advanced biliary tract cancer signals a poorer prognosis but offers a significant survival benefit when targeted with anti-HER2 therapies, advocating for routine screening and s
A Phase II trial investigating the combination of cabozantinib and nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) failed to meet its primary objective response rate endpoint, despite high rates of stable disease, highl
A Phase II trial demonstrates that the THAG regimen—combining immunotherapy, radiotherapy, and chemotherapy—significantly improves R0 resection rates and survival in patients with BRPC and LAPC, supported by IL-6 and ctDNA biomarker insight
A phase 1b/2 trial reveals that combining the bispecific antibody zanidatamab with tislelizumab and chemotherapy yields a 75.8% response rate and an impressive median overall survival of 32.4 months in first-line HER2-positive gastric and g
A prospective study demonstrates that concurrent antiviral prophylaxis effectively mitigates HBV reactivation risk in HCC patients treated with PD-1/L1 inhibitors, regardless of baseline viral load, challenging traditional clinical trial ex
A pooled analysis of the RAGNAR and LUC2001 trials demonstrates that erdafitinib provides a robust objective response rate of 55% and a median overall survival of 18.1 months in pretreated patients with FGFR-altered advanced cholangiocarcin
A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing crit
A multi-center study reveals that extensive dissection of non-metastatic tumor-draining lymph nodes reduces immunotherapy efficacy in recurrent biliary tract cancer by depleting crucial reservoirs of memory T cells and dendritic cells.
Open language-specific specialty feeds and department pages.